Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
PLoS Pathog ; 13(11): e1006703, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29108000

RESUMO

Host genetic variation modifying HIV-1 acquisition risk can inform development of HIV-1 prevention strategies. However, associations between rare or intermediate-frequency variants and HIV-1 acquisition are not well studied. We tested for the association between variation in genic regions and extreme HIV-1 acquisition phenotypes in 100 sub-Saharan Africans with whole genome sequencing data. Missense variants in immunoglobulin-like regions of CD101 and, among women, one missense/5' UTR variant in UBE2V1, were associated with increased HIV-1 acquisition risk (p = 1.9x10-4 and p = 3.7x10-3, respectively, for replication). Both of these genes are known to impact host inflammatory pathways. Effect sizes increased with exposure to HIV-1 after adjusting for the independent effect of increasing exposure on acquisition risk. TRIAL REGISTRATION: ClinicalTrials.gov NCT00194519; NCT00557245.


Assuntos
Antígenos CD/genética , Predisposição Genética para Doença , Infecções por HIV/genética , Glicoproteínas de Membrana/genética , Fatores de Transcrição/genética , Enzimas de Conjugação de Ubiquitina/genética , Sequenciamento Completo do Genoma , População Negra , Variação Genética/genética , Estudo de Associação Genômica Ampla , Infecções por HIV/transmissão , HIV-1/genética , Humanos , Fenótipo , Polimorfismo de Nucleotídeo Único/genética , Risco , Comportamento Sexual
3.
Clin Infect Dis ; 62(4): 456-61, 2016 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-26578538

RESUMO

BACKGROUND: The efficacy of condoms for protection against transmission of herpes simplex virus type 2 (HSV-2) has been examined in a variety of populations with different effect measures. Often the efficacy has been assessed as change in hazard of transmission with consistent vs inconsistent use, independent of the number of acts. Condom efficacy has not previously measured on a per-act basis. METHODS: We examined the per-act HSV-2 transmission rates with and without condom use among 911 African HSV-2 and human immunodeficiency virus type 1 (HIV-1) serodiscordant couples followed for an average of 18 months in an HIV prevention study. Infectivity models were used to associate the log10 probability of HSV-2 transmission over monthly risk periods with reported numbers of protected and unprotected sex acts. Condom efficacy was computed as the proportionate reduction in transmission risk for protected relative to unprotected sex acts. RESULTS: Transmission of HSV-2 occurred in 68 couples, including 17 with susceptible women and 51 with susceptible men. The highest rate of transmission was from men to women: 28.5 transmissions per 1000 unprotected sex acts. We found that condoms were differentially protective against HSV-2 transmission by sex; condom use reduced per-act risk of transmission from men to women by 96% (P < .001) and marginally from women to men by 65% (P = .060). CONCLUSIONS: Condoms are recommended as an effective preventive method for heterosexual transmission of HSV-2.


Assuntos
Preservativos , Transmissão de Doença Infecciosa/prevenção & controle , Infecções por HIV/complicações , Herpes Genital/prevenção & controle , Herpes Genital/transmissão , Herpesvirus Humano 2/isolamento & purificação , Controle de Infecções/métodos , Características da Família , Feminino , Humanos , Masculino , Medição de Risco
4.
PLoS One ; 4(4): e5272, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19404392

RESUMO

BACKGROUND: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort. METHODS: HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed. RESULTS: Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon (<5%), except for Trichomonas vaginalis in 14% of HIV-1 infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma RNA was 4.2 log(10) copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender (+0.24 log(10) copies/mL; p<0.001) and CD4 count (-0.25 and -0.55 log(10) copies/mL for CD4 350-499 and >500 relative to <350, respectively, p<0.001). CONCLUSIONS: The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1 transmission. TRIAL REGISTRATION: ClinicalTrials.gov NCT00194519.


Assuntos
Infecções por HIV/transmissão , HIV-1 , Herpes Genital/tratamento farmacológico , Herpesvirus Humano 2 , Parceiros Sexuais , Aciclovir/administração & dosagem , Adulto , África , Antivirais/uso terapêutico , Contagem de Linfócito CD4 , Estudos de Coortes , Feminino , Seguimentos , Infecções por HIV/prevenção & controle , HIV-1/genética , Heterossexualidade , Humanos , Masculino , RNA Viral/sangue , Infecções Sexualmente Transmissíveis
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA